Genetic Testing Helps Personalize Breast Cancer Treatment Decisions
October is breast cancer awareness month and according to the American Cancer Society, 1 in 8 U.S. women will be diagnosed with breast cancer in their lifetime. In 2018, about 266,000 new cases of breast cancer will be diagnosed and 41,000 women will die from this disease.
Although good progress is being made in the fight against breast cancer, it is still the second leading cause of cancer deaths for women in the U.S.
Personalized medicine is one approach doctors are using to find the best treatment options for patients. The two questions that newly diagnosed women often ask their doctors are: Will I die from this cancer and what are my treatment options?
Fortunately, advances in genetic testing are helping to answer these important questions.
There’s an important new genetic test called EndoPredict® that can predict the risk of a woman’s breast cancer returning within 10 years after surgery. EndoPredict analyzes 12 genes and offers a clear low- or high-risk result and provides an individualized test report for each patient to discuss with their doctor. EndoPredict helps determine which women can consider safely forgoing chemotherapy.
EndoPredict is truly personalized medicine.
For more information on EndoPredict by Myriad Genetics, click here: https://endopredict.com/